Telehealth is Here to Stay: New 50 State Survey of Commercial Insurance Laws Reveals Progress
02 December 2019
Two years after Foley’s 2017 Telemedicine and Digital Health Survey uncovered a demand for telemedicine and digital health services, as well as coverage and reimbursement to match the growing demand, Foley explores how each state has responded in its 2019 50-State Telehealth Survey plus District of Columbia (DC) of Commercial Payer Statutes.
The survey found that as of October 2019, 42 states maintain some sort of telehealth commercial payer law, however several of these state laws do not actually require coverage or payment parity.
Foley’s report breaks down variances in telehealth commercial statues state-by-state, including:
- States that have commercial payer statutes in place
- States that have coverage parity or limitations
- States that have payment parity
- States that impose originating site limits
- States that have patient cost shifting protection
- State laws that address telehealth narrow or exclusive networking
- States that require coverage of reimbursement of remote patient monitoring
- States that require coverage of store & forward/asynchronous telemedicine
To read the full survey, download the 2019 report.
Author(s)
Related Insights
13 May 2024
Labor & Employment Law Perspectives
Navigating the Rock & the Hard Place: Conflicting Federal and State Mandates for LGBTQ Employees
If employers have LGBTQ employees in certain states, they are now bumping up against the “rock” of federal laws, like Title VII and Title IX, and the “hard place” of conflicting state authority.
13 May 2024
Health Care Law Today
Medicaid: CMS Final Rules Aim to Expand Access, Provide Parity with Commercial Markets
The Centers for Medicare & Medicaid Services published two significant updates to its Medicaid regulations on May 10, 2024.
13 May 2024
PharmaPatents
USPTO Aims to Mow Down Patent Thickets
In a stunning Federal Register Notice published May 10, 2024, the U.S. Patent and Trademark Office proposes to impose a new requirement on terminal disclaimers filed to overcome obviousness-type double patenting rejections.